A Cohort Study of Plasma Cell Disorders (PCDs) in PKUFH

Amyloidosis, Castleman's Disease, Cryoglobulinemia, Heavy Chain Deposition Disease, Light Chain Deposition Disease, Monoclonal Gammopathy of Neurological Significance (MGNS), Monoclonal Gammopathy of Renal Significance (MGRS), Monoclonal Gammopathy of Undetermined Significance (MGUS), Multiple Myeloma, Plasma Cell Leukemia, Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes, Smoldering Multiple Myeloma

The primary aim is to establish a prospective cohort of patients with plasma cell disorders (PCDs). All of the hospitalized PCD patients who are willing to sign the informed consent form (ICF) will be included in this study. Clinical characteristics, treatment options and responses will be collected. Peripheral blood, bone marrow aspirate and urine samples before and after the treatment will banked for future research. Our team will focus on the clinical and pathological features of PCDs, the correlation between the minimal residual disease (MRD) status and prognosis, and the role of Tumor Microenvironment (TME) in the pathogenesis and progress of PCDs.

Primary 1. To establish a prospective cohort of patients with PCDs in PKUFH. 2. To dynamically analyze the relation between MRD status and prognosis, and the possible role of TME in PCD patients. Secondary To collect peripheral blood, bone marrow aspirate and urine samples from PCD patients for future study, such as the tumor clone selection and evolution. OUTLINE: PCD patients enrolled in this study will be assessed at baseline, clinical and laboratory data and biological samples be collected. Follow-up will be done at the 1, 3, 6, 12 months and then yearly after treatment.

No related papers found yet.

China